

Appl. No. 10/507,046
Amdt. Dated January 3, 2007
Reply to Office Action of October 3, 2006

Amendments to the Claims

This listing of claims will replace all prior version and listings of claims in the application:

Listing of Claims:

1. (Currently amended): An isolated ~~[[A]]~~ anti-anti-idiotypic antibody, characterized in that it
 - (i) reacts with an anti-idiotypic antibody which represents an internal image of the antigen CA125,
 - (ii) is specific for the tumour-associated antigen CA125 and reacts with this antigen, and
 - (iii) mediates an antibody-dependent cellular cytotoxicity against CA125-expressing tumour cells.
2. (Currently amended): The isolated ~~[[A]]~~ anti-anti-idiotypic antibody as claimed in claim 1, characterized in that it reacts with the monoclonal anti-idiotypic antibody ACA125 produced by the hybridoma 3D5~~[[()]]~~, which is deposited under DSM ACC2120~~[[()]]~~.
3. (Currently amended): The isolated ~~[[A]]~~ anti-anti-idiotypic antibody as claimed in claim 1 or claim 2, characterized in that it is produced as a result of a polyclonal immune response by vaccination with an anti-idiotypic antibody which represents an internal image of the antigen CA125.
4. (Currently amended): The isolated ~~[[A]]~~ anti-anti-idiotypic antibody as claimed in claim 1 or claim 2, characterized in that

Appl. No. 10/507,046

Amdt. Dated January 3, 2007

Reply to Office Action of October 3, 2006

it is produced recombinantly.

5. (Currently amended): The isolated ~~[[A]]~~ anti-anti-idiotypic antibody as claimed in claim 1 or claim 2, characterized in that it is produced by hybridoma cells as a monoclonal antibody.
6. (Currently amended): A ~~[[H]]~~ human hybridoma cell line which produces the monoclonal anti-anti-idiotypic antibody as claimed in claim 5.
7. (Currently amended): A ~~[[F]]~~ fragment of an anti-anti-idiotypic antibody as claimed in ~~any one of the claims~~ claim 1 ~~[[to 5]]~~, characterized in that it has the binding specificity of the anti-anti-idiotypic antibody.
8. (Currently amended): The ~~[[F]]~~ fragment as claimed in claim 7, characterized in that it comprises a Fab or F(ab)₂ fragment of the anti-anti-idiotypic antibody optionally coupled to a human Fc part.
9. (Currently amended): A ~~[[P]]~~ pharmaceutical composition comprising an anti-anti-idiotypic antibody as claimed in ~~any one of the claims~~ claim 1 to 5 ~~or a fragment as claimed in claim 7 or claim 8~~.
10. (Currently amended): The ~~[[P]]~~ pharmaceutical composition as claimed in claim ~~[[8]]~~ 9, characterized in that it additionally contains common pharmaceutical carriers and adjuvants.
11. (Currently amended): The ~~[[P]]~~ pharmaceutical composition as claimed in claim 9 or claim 10 for the treatment and/or prophylaxis of CA1125-expressing tumours.

Appl. No. 10/507,046

Amdt. Dated January 3, 2007

Reply to Office Action of October 3, 2006

12. (Withdrawn): Use of an anti-anti-idiotypic antibody as claimed in any one of the claims 1 to 5 or a fragment as claimed in claim 7 or claim 8 for the treatment and/or prophylaxis of CA125-expressing tumours.
13. (New): A pharmaceutical composition comprising a fragment as claimed in claim 7.
14. (New): A pharmaceutical composition comprising a fragment as claimed in claim 8.